Actual - Legal

Bayer's Trasylol problems are growing following increasing reports of the drug's side effects. Trasylol has recently been linked to a higher risk of kidney damage, heart attac

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

k, and death in the five years following a patient undergoing bypass heart surgery. In 1993 Trasylol (Aprotinin) was approved by the Federal Drug Administration. Aprotinin is

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

manufactured by Bayer under the brand name Trasylol. Over the past several years Trasylol sales continued to increase even though studies indicated serious Trasylol kidney dam

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

age side effects.

Most heart surgery patients don't know if they were given Trasylol during their open heart surgery. Many patients suffering from Trasylol kidney damage side

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

effects don't know if they were given Trasylol during their surgery because the surgeon made the decision whether to administer the drug to stop excessive bleeding during surg

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

ery.

Trasylol affects the way in which blood clots. It is given to open heart surgery patients to prevent excessive bleeding side effects. Trasylol is mainly used during repe

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

at coronary artery bypass surgery to reduce the amount of bleeding both during and after surgery. The drug has been in use for 13 years and a million patients have received it

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

. One of the most serious complications for bypass surgery patients is excessive bleeding. Clotting medications such as Trasylol reduce the amount of blood transfusion needed

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

uring surgery. In 2006 The New England Journal of Medicine (NEJM) published a study that reported Trasylol problems with an increased risk of developing heart failure, kidney

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

damage, myocardial infarction, and stroke in bypass heart surgery patients.

On September 21, 2006 the FDA's Cardiovascular and Renal Drug Advisory Committee met to evaluate c

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

urrent data regarding Trasylol side effects. On September 29, 2006, the FDA issued a public health advisory stating that it had new information that Bayer failed to disclose a

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

n earlier study that it had conducted involving 67,000 heart surgery patients. Preliminary review of this study suggested that Trasylol side effects included higher risks for

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

troke, congestive heart failure, kidney damage, and death. Bayer failed to disclose this study during the Advisory Committee on September 21, 2006.

Dr. Dennis Mangano, the le

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ad author of the NEJM Trasylol side effects study, has noted that Trasylol problems occurred more frequently than those linked with the drug Vioxx. Dr. Mangano relates, "In fa

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ct our findings raise even more troubling concerns, for:
(1) aprotinin has been on the market for three times as long as Vioxx, yet few comprehensive safety studies have

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

been conducted since approval;
(2) the life-threatening complications with aprotinin found here occurred far more frequently than those with Vioxx; and
(3) far less

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

xpensive generic alternatives to aprotinin which are equally effective in limiting bleeding have been available, but have been underused."

The observational study concluded,

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

"Our findings raise serious concerns regarding the safety of an approved drug intended to limit blood loss in at-risk patients undergoing surgery." Mangano related his opinion

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

regarding the ongoing use of Trasylol, stating "In good conscience, I could not administer (Trasylol) to this group of patients, especially given the availability of safer al

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

ternatives." Trasylol problems continue to be studied and the FDA is monitoring Trasylol kidney damage side effects and advising physicians to consider limiting the drug's use

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.actual.org.ua/article/130900/actual-Trasylol-Kidney-Damage-Side-Effects.html">Trasylol Kidney Damage Side Effects</a>

BB link (for phorums):
[url=http://www.actual.org.ua/article/130900/actual-Trasylol-Kidney-Damage-Side-Effects.html]Trasylol Kidney Damage Side Effects[/url]

Besides the article marketing, video marketing is another online marketing technique that can drive tons of traffic at low cost. Hence, you should not ignore this effective marketing technique, instead you should learn how to take advantage of this video opportunity for the sake of your own marketing objectives and goals to drive internet traffic to your website.

Somebody needs to care about what you think or you might as well be talking to the wall. The Internet allows you to blog about anything you want. It doesn't automatically create readers though.

Here we will look at a trading opportunity we looked at recently and look at two more that are shaping up right now. Let’s look at them.

Tags

Links

Actual - Trasylol Kidney Damage Side Effects

Related Articles: